To address the growing demand for fully human antibody drugs, Biocytogen has developed an advanced fully human antibody platform, RenMice, with cutting-edge technology. The proprietary RenMiceTM platform consists of RenMabTM mice, common light chain RenLite® mice and RenNano® mice, which enables new drug development with diverse modalities, including fully human monoclonal antibody drugs, bispecific/multispecific antibody drugs, and nanobody drugs.
Biocytogen's proprietary technology SUPCE enables in situ large-fragment replacement. Using this method, RenMice has mouse gene sequences replaced with human antibody gene sequences while retaining sequences of the mouse Fc region. This ensures production of fully human antibodies while maintaining normal immune system development. The RenMice platform produces highly diverse and specific antibodies with high affinity, making it ideal for developing effective antibody drugs.
RenMice Platform Introduction
RenMab Mouse
The RenMab™ mouse model completely replaced murine variable regions with full human heavy and kappa light chain V(D)J loci in situ. This results in a higher potential for antibody drug development, as the RenMab™ Mouse has a normal immune system comparable to that of wild-type mice and greater diversity of antibody genes. Researchers can use this platform to generate highly specific, diverse, and high-affinity antibody-based drugs.
RenLite Mouse
The RenLite® mouse model replaces murine heavy chain variable regions with human ones while replacing only one κ light chain VJ locus with its human counterpart. The resulting antibodies have diverse epitopes and high affinities like those produced by wild-type mice but also allow for more efficient downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs).
RenNano Mouse
The RenNano® mouse contains complete human heavy chain variable genes along with modified mouse constant regions. It generates heavy-chain-only antibodies (HCAbs) that exhibit great diversity and nM-level binding affinity independent of light chains. These HCAbs are ideal building blocks for bispecific/multispecific antibodies and CAR cell therapies since they can be used to derive single-domain antibodies (sdAbs), or nanobodies.
RenMice-based 6 Fully Human Antibody Discovery Platforms
News:
As of Dec 31, 2022, Biocytogen has reached 17 RenMiceTM licensing agreements with companies around the world; 40 projects are ongoing.
1. Biocytogen Expands Partnership with Merck
2. Biocytogen Signs RenMab/RenLite Licensing Agreement with BeiGene
3. Biocytogen Enters into RenMab™/RenLite® Licensing Agreement with Xencor
4. Biocytogen Announces RenLite Licensing Agreement with Janssen
